热门
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
文献类型：期刊论文
| 作者 | Li, Heng3,4; Zuo, Jianping1,3 ; Tang, Wei2,3,4
|
| 刊名 | FRONTIERS IN PHARMACOLOGY
 |
| 出版日期 | 2018-10-17 |
| 卷号 | 9 |
| 关键词 | phosphodiesterase-4 psoriasis atopic dermatitis inflammatory airway diseases inflammatory bowel disease roflumilast apremilast crisaborole |
| ISSN号 | 1663-9812 |
| DOI | 10.3389/fphar.2018.01048 |
| 文献子类 | Review |
| 英文摘要 | Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity. Inhibition of PDE4 is predicted to have diverse effects via the elevation of the level of cyclic adenosine monophosphate (cAMP) and the subsequent regulation of a wide array of genes and proteins. It has been identified that PDE4 is a promising therapeutic target for the treatment of diverse pulmonary, dermatological, and severe neurological diseases. Over the past decades, numerous PDE4 inhibitors have been designed and synthesized, among which roflumilast, apremilast, and crisaborole were approved for the treatment of inflammatory airway diseases, psoriatic arthritis, and atopic dermatitis, respectively. It is regrettable that the dramatic efficacies of a drug are often accompanied by adverse effects, such as nausea, emesis, and gastrointestinal reactions. However, substantial advances have been made to mitigate the adverse effects and obtain better benefit-to-risk ratio. This review highlights the dialectical role of PDE4 in drug discovery and the disquisitive details of certain PDE4 inhibitors to provide an overview of the topics that still need to be addressed in the future. |
| WOS关键词 | OBSTRUCTIVE PULMONARY-DISEASE ; CRISABOROLE TOPICAL OINTMENT ; MODERATE ATOPIC-DERMATITIS ; SELECTIVE PDE4 INHIBITOR ; SEVERE PLAQUE PSORIASIS ; IN-VITRO ; KAPPA-B ; ANTIINFLAMMATORY ACTIVITY ; BEHCETS-SYNDROME ; BETA(2)-ADRENOCEPTOR AGONIST |
| 资助项目 | National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, China[2018ZX09711002-006-011] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000447502000001 |
| 出版者 | FRONTIERS MEDIA SA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/279530]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Zuo, Jianping; Tang, Wei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai, Peoples R China; 2.Pilot Natl Lab Marine Sci & Technol, Open Studio Druggabil Res Marine Nat Prod, Qingdao, Peoples R China 3.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China; 4.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Antiinflammat, Shanghai, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Li, Heng,Zuo, Jianping,Tang, Wei. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases[J]. FRONTIERS IN PHARMACOLOGY,2018,9. |
| APA | Li, Heng,Zuo, Jianping,&Tang, Wei.(2018).Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.FRONTIERS IN PHARMACOLOGY,9. |
| MLA | Li, Heng,et al."Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases".FRONTIERS IN PHARMACOLOGY 9(2018). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。